

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Sisram Medical Ltd**

*(Incorporated in Israel with limited liability)*

**(Stock Code: 1696)**

### **CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Sisram Medical Ltd (the “**Company**”) dated 16 November 2018 (the “**Announcement**”) in relation to the proposed acquisition of an aggregate of 60% equity interest in Nova Medical Israel Ltd..

The Company wishes to clarify that due to inadvertent typographical error, the Hong Kong dollar amount for the net profit after taxation and extraordinary items of the Target Company (as defined in the Announcement) for the year ended 31 December 2017 as mentioned on page 7 of the Chinese version of the Announcement shall be revised to approximately HK\$16,709,230. The English version of the Announcement is not required to be changed.

Save as disclosed above, all the information in the Announcement remain unchanged.

On Behalf of the Board  
**Sisram Medical Ltd**  
**Yi LIU**  
*Chairman*

Hong Kong, 18 November 2018

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jianping HUA as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*